http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101658163-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2525-143 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-603 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0606 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0607 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6897 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-074 |
| filingDate | 2014-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101658163-B1 |
| titleOfInvention | A Method for Inhibition of Pluripotent stem cell-derived Teratoma Formation |
| abstract | The present invention relates to a method of inhibiting teratoma formation from undifferentiated pluripotent stem cells. The use of compounds exhibiting selective apoptosis in undifferentiated PSCs among the conventional methods of inhibiting the formation of teratomas has had unexpected toxicity or side effects despite high efficiency, but the method of the present invention does not use any additional compounds for the selective killing of undifferentiated PSCs It is possible to completely eliminate the undifferentiated PSC only by a simple visual light exposure. In addition, although the conventional method can inhibit the formation of the teratoma, the method of the present invention can remove the undifferentiated stem cells at an efficiency of 100%, and it is possible to prevent the teratoma formation and tumor formation from undifferentiated stem cells Can be completely excluded. Since the possibility of formation of teratoma and tumor formation is excluded 100%, the stem cells prepared by the method of the present invention can be applied to a wide range of clinical applications, and commercialization and clinical application in a short time as a stem cell treatment agent will be possible. |
| priorityDate | 2014-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 560.